ADB-FUBIATA

ADB-FUBINACA is a synthetic cannabinoid that is commonly used in designer drugs. It was first identified in Japan in 2013, and has since been found in various parts of the world. ADB-FUBINACA is known for its potent psychoactive effects, and is often used as a substitute for cannabis.

History

ADB-FUBINACA was first synthesized by the pharmaceutical company Pfizer as a potential medication for pain relief. However, it was never approved for medical use. The compound was later identified in synthetic cannabis blends in Japan in 2013, marking its emergence in the illicit drug market.

Chemistry

ADB-FUBINACA is a synthetic cannabinoid, meaning it mimics the effects of natural cannabinoids found in the cannabis plant. It is part of the indazole class of cannabinoids and is structurally related to other synthetic cannabinoids such as AB-FUBINACA and 5F-ADB.

Effects

The effects of ADB-FUBINACA are similar to those of cannabis, but are often more intense due to the high potency of the compound. Users may experience feelings of euphoria, altered perception, and increased appetite. However, ADB-FUBINACA can also cause negative effects such as anxiety, paranoia, and in severe cases, seizures or loss of consciousness.

Legal Status

The legal status of ADB-FUBINACA varies by country. In the United States, it is classified as a Schedule I controlled substance, meaning it has a high potential for abuse and no accepted medical use. It is also illegal in many other countries, including the United Kingdom, Canada, and Australia.

See Also

• Synthetic cannabinoids
• Designer drugs
• Cannabis (drug)